Yu-Han Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yu-Han Hu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chun Lin
Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
1 shared publication - Fan Zhang
Department of Pathophysiology, Guizhou Medical University, Guiyang, China
1 shared publication - Hui-Fang Zhu
Department of Pathology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, 453003 China
1 shared publication - Hui-Mei Zou
Department of Pathophysiology, Guizhou Medical University, Guiyang, China
1 shared publication - Jian-Ming Zhang
Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, People's Republic of China
1 shared publication - Qing Chen
Department of Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
1 shared publication
Latest Publications
- Open Access
- 3 September 2018
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 1-10
MiR-384 inhibits the proliferation of colorectal cancer by targeting AKT3
Growing evidence suggests that MiRNAs play essential roles in the initiation and progression of colorectal cancer (CRC). The aberrant expression of miR-384 has been reported in some cancers. However, the role and mechanism of miR-384 in CRC proliferation remains unknown. The expression of miR-384 was detected in CRC and their paired normal tissues by real-time PCR. In vivo and in vitro assays were conducted to confirm the role of miR-384 in the proliferation of CRC. Bioinformatics analysis, luciferase reporter assays, western blot and in vitro assays were used to confirm that AKT3 was the target gene of miR-384. Finally, Spearman’s correlation analyses was carried out to analyze the relationship between miR-384 expression and AKT3 expression in CRC. MiR-384 was down‑regulated in CRC tissues. The in vivo and vitro functional assays verified that the ectopic upregulation of miR-384 inhibited the proliferation of CRC and the inhibition of miR-384 promoted the proliferation of CRC. Bioinformatics analysis, luciferase reporter assays, western blot and in vitro functional assays confirmed AKT3 as the target gene of miR-384. The expression of miR-384 was negatively correlated with the expressions of AKT3. Our study verified that miR-384 could significantly suppress the proliferation of CRC by directing targeting AKT3.
- 3 September 2018
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 1-10
Open AccessMiR-384 inhibits the proliferation of colorectal cancer by targeting AKT3
Growing evidence suggests that MiRNAs play essential roles in the initiation and progression of colorectal cancer (CRC). The aberrant expression of miR-384 has been reported in some cancers. However, the role and mechanism of miR-384 in CRC proliferation remains unknown. The expression of miR-384 was detected in CRC and their paired normal tissues by real-time PCR. In vivo and in vitro assays were conducted to confirm the role of miR-384 in the proliferation of CRC. Bioinformatics analysis, luciferase reporter assays, western blot and in vitro assays were used to confirm that AKT3 was the target gene of miR-384. Finally, Spearman’s correlation analyses was carried out to analyze the relationship between miR-384 expression and AKT3 expression in CRC. MiR-384 was down‑regulated in CRC tissues. The in vivo and vitro functional assays verified that the ectopic upregulation of miR-384 inhibited the proliferation of CRC and the inhibition of miR-384 promoted the proliferation of CRC. Bioinformatics analysis, luciferase reporter assays, western blot and in vitro functional assays confirmed AKT3 as the target gene of miR-384. The expression of miR-384 was negatively correlated with the expressions of AKT3. Our study verified that miR-384 could significantly suppress the proliferation of CRC by directing targeting AKT3.
- 1 August 2017
- Published by Elsevier in Cellular Signalling
- Vol. 36, 67-78
Identification of NCK1 as a novel downstream effector of STAT3 in colorectal cancer metastasis and angiogenesis
- 1 August 2017
- Published by Elsevier in Cellular Signalling
- Vol. 36, 67-78
Identification of NCK1 as a novel downstream effector of STAT3 in colorectal cancer metastasis and angiogenesis